Почетна › Неуробластом › Тексас
Kliničke studije za Неуробластом u državi Тексас
15 studija za Неуробластом traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
Zvanični tekst studije (na engleskom)
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Тражи се учесник
До 17 година · Оба пола · Ажурирано 13. 11. 2026. · NCT06831552Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
Тражи се учесникФаза 1/2
До 30 година · Оба пола · Ажурирано 12. 11. 2026. · NCT06541262Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- и још 10
Тражи се учесникФаза 3
До 30 година · Оба пола · Ажурирано 30. 10. 2026. · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
Тражи се учесникФаза 1/2
6 Months – 25 Years · Оба пола · Ажурирано 30. 10. 2026. · NCT06395103Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
- UT Southwestern, Dallas
- Texas Tech University Health Sciences Center, Lubbock
Тражи се учесникФаза 1
12 Months – 20 Years · Оба пола · Ажурирано 8. 10. 2026. · NCT02013336PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Тражи се учесникФаза 1/2
Узраст од 1 до 30 · Оба пола · Ажурирано 6. 10. 2026. · NCT06721689Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Тражи се учесникФаза 2
До 22 година · Оба пола · Ажурирано 4. 9. 2026. · NCT02559778Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Тражи се учесникФаза 2
Узраст од 1 до 21 · Оба пола · Ажурирано 3. 9. 2026. · NCT06540963Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
Тражи се учесникФаза 1/2
До 26 година · Оба пола · Ажурирано 3. 9. 2026. · NCT06465199Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- и још 8
Тражи се учесникФаза 3
365 Days – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Тражи се учесникФаза 1/2
12 Months – 30 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
Тражи се учесникФаза 2
12 Months – 21 Years · Оба пола · Ажурирано 12. 8. 2026. · NCT05489887NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
Тражи се учесникФаза 1
Узраст од 1 до 24 · Оба пола · Ажурирано 21. 7. 2026. · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
Тражи се учесникФаза 2
Узраст од 1 до 31 · Оба пола · Ажурирано 20. 7. 2026. · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
Тражи се учесникОпсервациона студија
31 Days – 99 Years · Оба пола · Ажурирано 23. 3. 2026. · NCT01587300Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.